Form 4: Co-Diagnostics Director Eugene Durenard Acquires 30,000 Shares of Common Stock

Sentiment:

SEC Form 4


Director Eugene Durenard acquired 30,000 shares of Co-Diagnostics common stock on May 23, 2024, increasing his direct holdings to 115,000 shares.

Summary

  • On May 23, 2024, Eugene Durenard, a director of Co-Diagnostics, Inc., acquired 30,000 shares of common stock.
  • The acquisition was made at a price of $0.00 per share.
  • Following the transaction, Durenard directly owns 115,000 shares of Co-Diagnostics common stock.
  • Durenard also exercised 30,000 restricted stock units (RSUs) into common stock.
  • After the transaction, Durenard directly owns 200,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing regarding stock transactions by a company director. It doesn't inherently indicate positive or negative news about the company's performance.

Positives

  • A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and doesn't provide specific insights into Co-Diagnostics' competitive positioning or broader industry trends.

Stakeholder Impact

  • Shareholders may view the director's stock acquisition as a positive sign of confidence in the company.

Key Dates

DateDescription
July 7, 202270,000 restricted stock units awarded, vesting in six equal installments every six months commencing on November 23, 2022.
November 23, 2022Commencement date for vesting of 70,000 restricted stock units awarded on July 7, 2022.
January 17, 202340,000 restricted stock units awarded, vesting in six equal installments every six months commencing on May 23, 2023.
May 23, 2023Commencement date for vesting of 40,000 restricted stock units awarded on January 17, 2023.
June 12, 202370,000 restricted stock units awarded, vesting in six equal installments every six months commencing on November 23, 2023.
November 23, 2023Commencement date for vesting of 70,000 restricted stock units awarded on June 12, 2023.
May 23, 2024Date of transaction: acquisition of 30,000 shares of common stock and exercise of 30,000 restricted stock units.
May 28, 2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.